Navigation Links
Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Date:4/14/2011

NEW YORK, April 14, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

http://www.reportlinker.com/p0479828/Juvenile-Rheumatoid-Arthritis-JRA-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html

Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, "Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global Juvenile Rheumatoid Arthritis Therapeutics market. The report identifies the key trends shaping and driving the global Juvenile Rheumatoid Arthritis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Juvenile Rheumatoid Arthritis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Juvenile Rheumatoid Arthritis Therapeutics market. Its Scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Juvenile Rheumatoid Arthritis Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.

- Analysis of the current and future competition in the seven key countries Juvenile Rheumatoid Arthritis Therapeutics market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Juvenile Rheumatoid Arthritis Therapeutics therapeutics market.

- Analysis of key recent licensing and partnership agreements in Juvenile Rheumatoid Arthritis Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Juvenile Rheumatoid Arthritis Therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Juvenile Rheumatoid Arthritis Therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global Juvenile Rheumatoid Arthritis Therapeutics market landscape? – Identify, understand and capitalize.

1 Table of contents

1 Table of contents 2

1.1 List of Tables 4

1.2 List of Figures 5

2 JRA Therapeutics: Introduction 6

2.1 Disease Overview 6

2.2 Etiology and Pathophysiology 7

2.3 Signs and Symptoms 7

2.4 Epidemiology 8

2.5 Diagnosis 8

2.6 Treatment and Management Pattern 10

2.7 GlobalData Pipeline Report Guidance 11

3 JRA Therapeutics Market: Market Characterization 12

3.1 Global, Market Size (2005-2010) 12

3.2 Global, Market Forecast (2010-2017) 13

3.3 The US Market Size (2005-2010) 14

3.4 The US Market Forecast (2010-2017) 15

3.5 France Market Size (2005-2010) 16

3.6 France Market Forecast (2010-2017) 17

3.7 Germany Market Size (2005-2010) 18

3.8 Germany Market Forecast (2010-2017) 19

3.9 Italy Market Size (2005-2010) 20

3.10 Italy Market Forecast (2010-2017) 21

3.11 Spain Market Size (2005-2010) 22

3.12 Spain Market Forecast (2010-2017) 23

3.13 The UK Market Size (2005-2010) 24

3.14 The UK Market Forecast (2010-2017) 25

3.15 Japan Market Size (2005-2010) 26

3.16 Japan Market Forecast (2010-2017) 27

3.17 Drivers and Barriers for the JRA Therapeutics Market 28

3.17.1 Drivers for the JRA Therapeutics Market 28

3.17.2 Barriers for the JRA Therapeutics Market 29

3.18 Opportunity and Unmet Need 29

3.19 Key Takeaway 31

4 JRA Therapeutics: Competitive Assessment 32

4.1 Overview 32

4.2 Strategic Competitor Assessment 32

4.3 Product Profile for the Major Marketed Products in the JRA Therapeutics Market 33

4.3.1 NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) 33

4.3.2 Steroids 34

4.3.3 Disease-Modifying Anti-Rheumatic Drugs (DMARDs) 34

4.3.4 Enbrel (etanercept) 35

4.3.5 Humira (adalimumab) 36

4.3.6 Orencia (abatacept) 37

4.4 Key Takeaway 38

5 JRA Therapeutics: Pipeline Assessment 39

5.1 Overview 39

5.2 Strategic Pipeline Assessment 39

5.3 JRA Therapeutics – Pipeline Analysis by Phase of Development 40

5.3.1 JRA Therapeutics – Filed and Phase III Clinical Pipeline 40

5.3.2 JRA Therapeutics Market – Phase II Clinical Pipeline 40

5.3.3 JRA Therapeutics Market – Phase I and Pre-clinical Pipeline 40

5.4 JRA Therapeutics – Pipeline by Mechanism of Action 41

5.5 Technology Trends Analytical Framework 42

5.6 JRA Therapeutics – Most Promising Drugs Under Clinical Development 43

5.7 Most Promising Drug Profiles 44

5.7.1 Actemra (tocilizumab) 44

5.7.2 Ilaris (Canakinumab, ACZ885) 45

5.8 Key Takeaway 45

6 JRA Therapeutics: Clinical Trials Mapping 46

6.1 Clinical Trials by Region/Country (the US, EU5 and Japan) 46

6.2 Clinical Trials by Phase of Clinical Development 47

6.3 Clinical Trials by Trial Status 48

6.4 Clinical Trials by Sponsors 49

6.5 Brief Profiles of Top Ten Companies Participating in Therapeutics Clinical Trials 50

7 JRA Therapeutics: Strategic Assessment 51

7.1 Key Events Impacting the Future Market 51

7.2 Future Market Competition Scenario 52

8 JRA Therapeutics: Future Players 53

8.1 Introduction 53

8.2 Company Profiles 54

8.2.1 Novartis AG 54

8.3 Hoffmann-La Roche 59

8.3.2 Centocor Ortho Biotech Inc. 61

8.3.3 Italfarmaco S.p.A. 62

8.4 Details of Other Companies in the Pipeline 64

8.5 Key Takeaway 64

9 JRA Therapeutics: Licensing and Partnership Deals 65

10 JRA Therapeutics: Appendix 66

10.1 Definition 66

10.2 Acronyms 66

10.3 Research Methodology 68

10.3.1 Coverage 68

10.3.2 Secondary Research 68

10.3.3 Forecasting 68

10.3.4 Primary Research 71

10.3.5 Expert Panel Validation 71

10.4 Contact Us 71

10.5 Disclaimer 71

10.6 Bibliography 72

1.1 List of Tables

Table 1: ILAR Classification, Inclusion and Exclusion Criteria for JRA, 2011 6

Table 2: Differential Diagnosis of Juvenile Idiopathic Arthritis in Children 8

Table 3: JRA Therapeutics Market, Global, Revenue ($m), 2005–2010 12

Table 4: JRA Therapeutics Market, Global, Market Forecast ($m), 2010–2017 13

Table 5: JRA Therapeutics Market, The US, Revenue ($m), 2005–2010 14

Table 6: JRA Therapeutics Market, The US, Market Forecast ($m), 2010–2017 15

Table 7: JRA Therapeutics Market, France, Revenue ($m), 2005–2010 16

Table 8: JRA Therapeutics Market, France, Market Forecast ($m), 2010–2017 17

Table 9: JRA Therapeutics Market, Germany, Revenue ($m), 2005–2010 18

Table 10: JRA Therapeutics Market, Germany, Market Forecast ($m), 2010–2017 19

Table 11: JRA Therapeutics Market, Italy, Revenue ($m), 2005–2010 20

Table 12: JRA Therapeutics Market, Italy, Market Forecast ($m), 2010–2017 21

Table 13: JRA Therapeutics Market, Spain, Revenue ($m), 2005–2010 22

Table 14: JRA Therapeutics Market, Spain, Market Forecast ($m), 2010–2017 23

Table 15: JRA Therapeutics Market, The UK, Revenue ($m), 2005–2010 24

Table 16: JRA Therapeutics Market, the UK, Market Forecast ($m), 2010–2017 25

Table 17: JRA Therapeutics Market, Japan, Revenue ($m), 2005–2010 26

Table 18: JRA Therapeutics Market, Japan, Market Forecast ($m), 2010–2017 27

Table 19: JRA Therapeutics, Filed and Phase III, Pipeline, 2011 40

Table 20: JRA Therapeutics, Phase II, Pipeline, 2011 40

Table 21: JRA Therapeutics, Pre-clinical Pipeline, 2011 40

Table 22: JRA Therapeutics, Global, Most Promising Drugs Under Clinical Development, 2011 43

Table 23: JRA Therapeutics, Global, Clinical Trials, 2011 46

Table 24: JRA Therapeutics, Global, Clinical Trials by Phase, 2011 47

Table 25: JRA Therapeutics, Global, Clinical Trials by Status of Development, 2011 48

Table 26: JRA Therapeutics, Global, Prominent Sponsors, 2011 49

Table 27: JRA Therapeutics, Global, Top Ten Companies by Phase by Clinical Trials, 2011 50

Table 28: Novartis Deals, Alliances and Partnerships, 2009-2010 56

Table 29: Novartis AG – JRA Pipeline Products, 2011 58

Table 30: Hoffmann-La Roche Inc. – Deals, Alliances and Partnerships, 2011 61

Table 31: Hoffmann-La Roche Inc – JRA Pipeline Products, 2011 61

Table 32: Centocor Ortho Biotech Inc. – Deals, Alliances and Partnerships, 2011 62

Table 33: Centocor Ortho Biotech Inc. – JRA Pipeline Products, 2011 62

Table 34: Italfarmaco S.p.A. – Deals, Alliances and Partnerships, 2011 63

Table 35: Italfarmaco S.p.A. – JRA Pipeline Products, 2011 63

Table 36: Description of Other Companies in the Pipeline, 2011 64

Table 37: JRA Therapeutics – Licensing and Partnership Deals, 2011 65

1.2 List of Figures

Figure 1: JRA Therapeutics, Etiology and Pathophysiology, 2011 7

Figure 2: JRA Therapeutics Market, Global, Revenue ($m), 2005–2010 12

Figure 3: JRA Therapeutics Market, Global, Market Forecast ($m), 2010–2017 13

Figure 4: JRA Therapeutics Market, The US, Revenue ($m), 2005–2010 14

Figure 5: JRA Therapeutics Market, The US, Market Forecast ($m), 2010–2017 15

Figure 6: JRA Therapeutics Market, France, Revenue ($m), 2005–2010 16

Figure 7: JRA Therapeutics Market, France, Market Forecast ($m), 2010–2017 17

Figure 8: JRA Therapeutics Market, Germany, Revenue ($m), 2005–2010 18

Figure 9: JRA Therapeutics Market, Germany, Market Forecast ($m), 2010–2017 19

Figure 10: JRA Therapeutics Market, Italy, Revenue ($m), 2005–2010 20

Figure 11: JRA Therapeutics Market, Italy, Market Forecast ($m), 2010–2017 21

Figure 12: JRA Therapeutics Market, Spain, Revenue ($m), 2005–2010 22

Figure 13: JRA Therapeutics Market, Spain, Market Forecast ($m), 2010–2017 23

Figure 14: JRA Therapeutics Market, The UK, Revenue ($m), 2005–2010 24

Figure 15: JRA Therapeutics Market, the UK, Market Forecast ($m), 2010–2017 25

Figure 16: JRA Therapeutics Market, Japan, Revenue ($m), 2005–2010 26

Figure 17: JRA Therapeutics Market, Japan, Market Forecast ($m), 2010–2017 27

Figure 18: Opportunity and Unmet Need in the JRA Therapeutics, 2011 30

Figure 19: Strategic Competitor Assessment of the Marketed Products in JRA, 2011 33

Figure 20: JRA Therapeutics – Clinical Pipeline by Mechanism of Action, 2011 41

Figure 21: JRA Therapeutics – Clinical Pipeline by Phase of Development, 2011 41

Figure 22: Technology Trends Analytics Framework, 2011 42

Figure 23: Technology Trends Analytics Framework – Description, 2011 42

Figure 24: JRA Therapeutics, Global, Clinical Trials by Country, 2011 46

Figure 25: JRA Therapeutics, Global, Clinical Trials by Phase, 2011 47

Figure 26: JRA Therapeutics, Global, Clinical Trials by Status of Development, 2011 48

Figure 27: JRA Therapeutics, Global, Overall Sponsors, 2011 49

Figure 28: JRA Therapeutics, Global, Prominent Sponsors, 2011 49

Figure 29: JRA Therapeutics, Global, Top Ten Companies by Phase, 2011 50

Figure 30: JRA Therapeutics, Drivers and Restraints, 2011 51

Figure 31: Implications for Future Market Competition in the JRA Therapeutics, 2011 52

Figure 32: JRA Therapeutics, Clinical Pipeline by Company, 2011 53

Figure 33: GlobalData Market Forecasting Model 70Novartis AG

Hoffmann-La Roche

Centocor Ortho Biotech Inc.

Italfarmaco S.p.A.

To order this report:

: Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Contact:
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... LONDON , February 10, 2016 ... 2016, which will be held at Victoria Park Plaza in ... host an informative seminar on technology and future advances for ... seminar, led by Lorna Graham , associate director of ... technology to keep up with new regulations and standards in ...
(Date:2/10/2016)... ATLANTA , Feb. 10, 2016  LexisNexis® ... and technology, today announced the launch of ... analytics solution that helps improve and optimize the ... evaluation of performance using severity-adjusted scores. By measuring ... a critical solution to deliver better outcomes, improve ...
(Date:2/10/2016)... SAN DIEGO , Feb. 10, 2016 ... biopharmaceutical company developing novel, clinical-stage therapies for sickle cell ... an underwritten public offering of 29,090,910 units at a ... unit consists of one share of the Company,s common ... the Company,s common stock at an exercise price of ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Intalere’s 2016 Executive Forum, taking ... of the country’s top healthcare executives to share insights on transformational strategies to ... Forum is the provider-centric perspective, experience, expertise and strategy shared by the participants,” ...
(Date:2/10/2016)... MA (PRWEB) , ... February 10, 2016 , ... Gout ... switch, and brings pain that is often severe, with intense swelling and redness. It ... than eight million people, but older adults are the most susceptible, according to the ...
(Date:2/10/2016)... ... ... Armune BioScience signed a definitive agreement with ARCpoint Labs ... country. Launched in April of 2015, Apifiny is the only cancer specific, non-PSA blood ... exceeded 3,000 tests in 2015. Primary care physicians and urologists have utilized Apifiny to ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric ... in their patients. Research shows that the Goal Attainment Scale (GAS) captures 20% ... this challenge and learn more about the Goal Attainment Scale, Education Resources Inc. ...
(Date:2/10/2016)... ... February 10, 2016 , ... A ... Safety Congress and Expo event March 9-11, 2016. Hosted by Ohio's Bureau of ... , As the longest running and largest worker's compensation event in Ohio, ...
Breaking Medicine News(10 mins):